دورية أكاديمية
Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome.
| العنوان: | Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome. |
|---|---|
| المؤلفون: | Dellinger RP; Division of Critical Care Medicine, Department of Medicine, Cooper University Hospital, 1 Cooper Plaza, Camden, NJ 08103, USA. dellinger-phil@cooperhealth.edu., Trzeciak SW, Criner GJ, Zimmerman JL, Taylor RW, Usansky H, Young J, Goldstein B |
| المصدر: | Critical care (London, England) [Crit Care] 2012 Dec 12; Vol. 16 (2), pp. R36. Date of Electronic Publication: 2012 Dec 12. |
| نوع المنشور: | Journal Article; Multicenter Study; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 9801902 Publication Model: Electronic Cited Medium: Internet ISSN: 1466-609X (Electronic) Linking ISSN: 13648535 NLM ISO Abbreviation: Crit Care Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London, UK : BioMed Central Ltd Original Publication: London : Current Science Ltd, c1997- |
| مواضيع طبية MeSH: | Nitric Oxide/*administration & dosage , Respiratory Distress Syndrome/*drug therapy, Administration, Inhalation ; Adult ; Area Under Curve ; Chi-Square Distribution ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Placebos ; Prospective Studies ; Respiratory Distress Syndrome/mortality ; Respiratory Distress Syndrome/physiopathology ; Respiratory Function Tests ; Statistics, Nonparametric ; Treatment Outcome |
| مستخلص: | Introduction: Assessment of treatments for acute respiratory distress syndrome (ARDS) has focused on short-term outcomes (for example, mortality); little information exists regarding long-term effects of ARDS treatment. Survivors of ARDS episodes may have long-term obstructive/restrictive pulmonary abnormalities and pulmonary gas exchange impairment. A 2004 prospective randomized placebo-controlled trial assessed the efficacy and safety of inhaled nitric oxide (iNO) in patients with non-septic ARDS; the primary endpoint was days alive and off assisted breathing. This analysis examined potential effects of iNO or placebo on pulmonary function six months post-treatment in ARDS survivors from that original study. Methods: ARDS survivors (N = 92) from a large-scale randomized, placebo-controlled study evaluating mortality after either 5 ppm iNO or placebo for up to 28 days were assessed six months post-treatment. Pulmonary function testing across seven parameters was conducted. Results: At 6 months post-treatment, results indicated significantly better absolute values for iNO versus placebo for mean ± SD total lung capacity (TLC, 5.54 ± 1.42 vs. 4.81 ± 1.00; P = 0.026). There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV1, 80.23 ± 21.21 vs. 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs. 69.84 ± 27.40; P = 0.019), c) FEV1/FVC (96.14 ± 13.79 vs. 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs. 76.10 ± 21.84; P < 0.001). Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion. Conclusions: ARDS patients surviving after treatment with low-dose iNO had significantly better values for select pulmonary function tests at six months post-treatment than placebo-treated patients. Further trials are warranted to determine the effects of iNO on chronic lung function in ARDS survivors, a factor in long-term morbidity and quality of life in this population. Trial Registration: A Double-blind, Randomized, Placebo-controlled, Dose-response Study of Inhaled Nitric Oxide in the Treatment of Acute Respiratory Distress Syndrome. NCT number: ISRCTN53268296. |
| References: | JAMA. 2004 Apr 7;291(13):1603-9. (PMID: 15069048) JAMA. 1999 Jan 27;281(4):354-60. (PMID: 9929089) Intensive Care Med. 1997 Jan;23(1):51-7. (PMID: 9037640) Chest. 2005 Aug;128(2):525-32. (PMID: 16100134) N Engl J Med. 2000 May 4;342(18):1334-49. (PMID: 10793167) Crit Care Med. 1999 Nov;27(11):2367-74. (PMID: 10579250) Crit Care Med. 2005 Jul;33(7):1549-56. (PMID: 16003061) Chest. 1989 Jul;96(1):114-9. (PMID: 2661155) Crit Care Med. 2005 Jul;33(7):1656-8. (PMID: 16003085) Am J Respir Crit Care Med. 1996 Mar;153(3):985-90. (PMID: 8630584) Crit Care Med. 2006 Dec;34(12):2883-90. (PMID: 17075373) Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):602-11. (PMID: 8810593) Crit Care Med. 2003 Jun;31(6):1697-704. (PMID: 12794407) BMJ. 2007 Apr 14;334(7597):779. (PMID: 17383982) Crit Care Clin. 2002 Jan;18(1):45-68, vi. (PMID: 11910732) Am Rev Respir Dis. 1987 Aug;136(2):402-5. (PMID: 3039882) Treat Respir Med. 2004;3(5):307-28. (PMID: 15606221) Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1896-903. (PMID: 11734443) Chest. 2003 Mar;123(3):845-53. (PMID: 12628887) N Engl J Med. 2006 Apr 20;354(16):1671-84. (PMID: 16625008) N Engl J Med. 2004 Aug 26;351(9):884-92. (PMID: 15329426) Intensive Care Med. 2000 Sep;26(9):1304-11. (PMID: 11089757) Chest. 1994 Jan;105(1):190-4. (PMID: 8275731) Br J Pharmacol. 1999 Apr;126(8):1856-62. (PMID: 10372830) Chest. 2005 Oct;128(4):2910-7. (PMID: 16236968) N Engl J Med. 2003 Feb 20;348(8):683-93. (PMID: 12594312) Clin Pharmacol Ther. 1985 Apr;37(4):391-5. (PMID: 3979000) |
| سلسلة جزيئية: | ISRCTN ISRCTN53268296 |
| المشرفين على المادة: | 0 (Placebos) 31C4KY9ESH (Nitric Oxide) |
| تواريخ الأحداث: | Date Created: 20120306 Date Completed: 20160509 Latest Revision: 20220408 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC3681348 |
| DOI: | 10.1186/cc11215 |
| PMID: | 22386043 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1466-609X |
|---|---|
| DOI: | 10.1186/cc11215 |